Vaccine startup Genocea Biosciences Inc. raised another $30 million to support its two lead programs, the company said Oct. 10. The Series C financing largely is intended to support an early-stage trial of its therapeutic vaccine for the herpes simplex type 2 virus.
Two new investors backed Genocea in the round – the Bill & Melinda Gates Foundation and CVF, an affiliate of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?